Urologic Oncology Research Symposium: "Immune Checkpoint Inhibitors: Impact of Macro and Microenvironment on Efficacy“ (2020)
Available on Friday, July 10
Rapid growth in the field of immune checkpoint inhibition has transformed treatment paradigms for genitourinary cancers, and the use of immunotherapy is under active investigation in almost all genitourinary malignancies and disease states. This webcast will provide opportunities for new knowledge about the tumor immune microenvironment of genitourinary tumors as well as host factors that may impact immune checkpoint (IC) response, and explore novel targets as well as non-IC immunotherapy modalities.
Registration Fees
Member Category |
|
---|---|
AUA Member | Free |
AUA Non-Member | $29.00 |
Presentations
Welcome and Opening Remarks | Peter Black, MD, FACS, FRCSC |
Session One: Bladder Cancer | Moderator: David McConkey, PhD |
scRNAseq of urothelial cancer: comprehensive analysis of the tumor microenvironment | John P. Sfakianos, MD |
Role of the microenvironment in response to BCG treatment of bladder cancer | Robert Svatek, MD |
FGFR3 Alterations Regulate the Tumor Immune Environment and Impact Response to Immunotherapy | Matthew D. Galsky, MD |
Session Two: Prostate Cancer | Moderator: Angelo De Marzo, MD, PhD |
The Rise, Fall and Resurrection of PROSTVAC | James Gulley, MD, PhD |
Session Three: Kidney Cancer | Moderator: Brian Shuch, MD |
Dissecting the Tumor Immune Microenvironment of Clear Cell Renal Cell Carcinoma | Yousef Zakharia, MD |
Phenotyping the ccRCC TME to identify therapeutic strategies | A. Ari Hakimi, MD |
Targeting the Adenosine Pathway as Another Immune Checkpoint in Renal Cell Carcinoma | Lawrence Fong, MD |
Session Four: General | Moderators: Peter Black, MD, FACS, FRCSC and William Kim, MD |
The Abscopal Effect Untangled | Kent W. Mouw, MD, PhD |
The Microbiome as an Immune Regulator | Karen S. Sfanos, PhD |